REDWOOD CITY, Calif.,
Oct. 10, 2014 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced
that multiple moderated poster presentations will be made at the
upcoming American Society of Anesthesiologists (ASA 2014) meeting
October 11th to
October 15th, 2014 at the
Ernest N. Morial Convention Center in New
Orleans, LA. The annual ASA meeting is the premier
anesthesiology educational event in the world with more than 15,000
attendees from over 90 countries expected to attend.
Pamela Palmer, M.D. Ph.D. will present safety and efficacy
data from the phase 3 trials evaluating the Zalviso™ sufentanil
sublingual tablet system, under FDA evaluation for the potential
treatment of moderate-to-severe acute pain in the hospital
setting. Results from a phase 2, dose-finding study of a
second sublingual sufentanil product candidate will also be
presented.
Details on the presentation times are as follows:
Saturday, October 11, 2014 –
Moderated Poster Session, Hall B1, Area E, Poster A1225, Monitor 2
– Presentation time 11:30-12:00 Noon (local time)
Authors:
|
Pamela Palmer, MD,
PhD, Harold Minkowitz, MD, Tong-Joo Gan, MD
|
|
|
Title:
|
A PHASE 3
META-ANALYSIS OF OPIOID ADVERSE EVENTS WITH ZALVISO (SUFENTANIL
SUBLINGUAL TABLET SYSTEM) COMPARED TO IV PATIENT-CONTROLLED
ANALGESIA WITH MORPHINE
|
Saturday, October 11, 2014 –
Moderated Poster Session, Hall B1, Area E, Poster A1300, Monitor 1
– Presentation time 2:00-2:30pm
(local time)
Authors:
|
Pamela P. Palmer, MD,
PhD, Neil K. Singla, MD, Derek D. Muse, MD, Mark A. Evashenk,
BS
|
|
|
Title:
|
SUFENTANIL
SUBLINGUAL MICROTABLETS FOR ACUTE PAIN FOLLOWING BUNIONECTOMY:
EFFECT OF GENDER ON ANALGESIC RESPONSE
|
Monday, October 13, 2014 –
Moderated Poster Session, Hall B1, Area B, Poster A3302, Monitor 2
– Presentation time 1:00-1:30pm
(local time)
Authors:
|
Pamela P. Palmer, MD,
PhD, Harold S. Minkowitz, MD, Tong-Joo Gan, MD
|
|
|
Title:
|
A PHASE 3
META-ANALYSIS OF ONSET OF ANALGESIA FOR ZALVISO (SUFENTANIL
SUBLINGUAL TABLET SYSTEM) COMPARED TO IV PATIENT-CONTROLLED
ANALGESIA WITH MORPHINE
|
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, Zalviso, is designed
to improve the management of moderate-to-severe acute pain in adult
patients in the hospital setting by utilizing a high therapeutic
index opioid, through a non-invasive delivery route via a
pre-programmed, patient-controlled analgesia device. AcelRx has
announced positive results from each of the three completed Phase 3
clinical trials for Zalviso, and has submitted an NDA to the FDA
seeking approval for Zalviso in the treatment of moderate-to-severe
acute pain in adult patients in the hospital setting and on
July 25th, received a Complete
Response Letter from the FDA. AcelRx plans to initiate a
Phase 3 clinical trial for ARX-04, a product candidate for the
treatment of moderate-to-severe acute pain in a medically
supervised setting, by the end of 2014. The Company has two
additional pain treatment product candidates, ARX-02 and ARX-03,
which have completed Phase 2 clinical development. For
additional information about AcelRx's clinical programs, please
visit www.acelrx.com.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
SOURCE AcelRx Pharmaceuticals, Inc.